Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3534 - Tumor-stroma interactions as a determinant of drug resistance in BRAF-mut melanoma.

Date

10 Sep 2017

Session

Poster display session

Presenters

Italia Falcone

Citation

Annals of Oncology (2017) 28 (suppl_5): v428-v448. 10.1093/annonc/mdx377

Authors

I. Falcone1, R. Loria2, U. Cesta Incani1, L. Ciuffreda1, C. Bazzichetto1, F. Conciatori1, B. Bellei3, D. Kovacs3, M. Picardo3, R. Falcioni2, M. Milella1

Author affiliations

  • 1 Medical Oncology 1, Regina Elena National Cancer Institute, 00144 - Rome/IT
  • 2 Department Of Research Advanced Diagnostic And Technological Innovation, Regina Elena National Cancer Institute, 00144 - Rome/IT
  • 3 Of Cutaneous Physiopathology And Integrated Center Of Metabolomics Research, San Gallicano Dermatologic Institute, 00144 - Rome/IT
More

Resources

Abstract 3534

Background

In BRAF-mut melanoma combined BRAF/MEK inhibition increases survival; however, pharmacological effects on the genetically “normal” tumor microenvironment (i.e. paradox MAPK activation) may set the stage for the development of drug resistance.

Methods

GFP-labeled cutaneous fibroblasts (HFF) were co-cultured with melanoma cells, in the presence or absence of direct cell-cell contact, and response to Dabrafenib (D) and Trametinib (T), alone or combined, was monitored over time. SEMA6A and AXL were preliminarily evaluated as potential mediators of such interactions.

Results

HFF significantly protected (60-100% protection at the lowest two drug concentrations) BRAF-mut M14 melanoma cells from the growth inhibitory activity of D and T, alone or combined; however, combined D+T at the highest concentrations overcame stroma-mediated protection and eliminated both cell populations. Thus, combined BRAF/MEK inhibition resulted in strongly synergistic interactions, as compared to single agent treatments, only under co-culture conditions (CI 0.6 and 0.2 for M14 and HFF cells, respectively). Protective melanoma/stroma interactions were mediated by direct cell-cell contact, as co-cultures in trans-well Boyden chambers or isolated cultures using conditioned medium (HFF-conditioned medium for M14; M14-conditioned medium for HFF), did not affect pharmacological response. As SEMA6A expression is tightly controlled by MAPK and AXL mediates resistance to MAPK inhibition in melanoma, we assessed their potential as mediators of stroma-mediated melanoma protection: interestingly, SEMA6A and AXL expression in a panel of melanoma cell lines were inversely correlated; moreover, in cell lines derived by primary and cutaneous metastases of the same patient, AXL expression was upregulated at the mRNA and protein level in cells derived from metastatic lesions.

Conclusions

Tumor-stroma interactions protect BRAF-mut melanoma from MAPK inhibition; such functional protection is mediated by cell-cell contact. SEMA6A and AXL are possible mediators of this interaction and their reciprocal relationships are being studied in melanoma cell line models and clinical series.

Clinical trial identification

Legal entity responsible for the study

Regina Elena Cancer Institute- San Gallicano Dermatologic Institute

Funding

AIRC (18622-14362-9979)

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.